Gaylord Specialty Healthcare First in Nation to Adopt Ground-Breaking Pharyngeal Electrical Stimulation Technology to Treat Patients with Dysphagia

NEWS PROVIDED BY

Gaylord Specialty Healthcare 

09 May, 2023, 15:45 ET

WALLINGFORD, Conn., May 9, 2023 /PRNewswire/ — Gaylord Specialty Healthcare, a nonprofit rehabilitation-focused healthcare system, is proud to announce that it is the first healthcare organization in the nation to use the Phagenyx® Neurostimulation System from Phagenesis, Ltd. to treat dysphagia among stroke patients.

Dysphagia – or the difficulty or inability to swallow – affects millions worldwide and is a common diagnosis among adult patients at long-term acute care hospitals, including Gaylord Hospital. Dysphagia following stroke is most often caused by damage to the parts of the brain that control and coordinate swallowing and can lead to serious medical complications, including aspiration pneumonia.

The device uses first-of-its-kind Pharyngeal Electrical Stimulation (PES) technology to precisely target and stimulate sensory nerves within the pharyngeal mucosa critical for safe and efficient swallowing function. Clinical studies have shown PES using the FDA-approved Phagenyx device can improve swallowing function, reduce aspiration risk, and improve patient outcomes. The device has received regulatory approval in multiple countries and is used in leading hospitals and rehabilitation centers worldwide.

Read more here.